176 related articles for article (PubMed ID: 38520019)
41. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
42. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Wang R; Zhang T; Yang Z; Jiang C; Seng J
J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
[TBL] [Abstract][Full Text] [Related]
43. LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/β-catenin Signaling.
Tang T; Guo C; Xia T; Zhang R; Zen K; Pan Y; Jin L
Theranostics; 2019; 9(24):7384-7402. PubMed ID: 31695775
[No Abstract] [Full Text] [Related]
44. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
45. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
46. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
[TBL] [Abstract][Full Text] [Related]
47. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway.
Qiao Y; Wang B; Yan Y; Niu L
Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485
[TBL] [Abstract][Full Text] [Related]
48. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
49. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
50. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.
Liu Y; Choi DS; Sheng J; Ensor JE; Liang DH; Rodriguez-Aguayo C; Polley A; Benz S; Elemento O; Verma A; Cong Y; Wong H; Qian W; Li Z; Granados-Principal S; Lopez-Berestein G; Landis MD; Rosato RR; Dave B; Wong S; Marchetti D; Sood AK; Chang JC
Stem Cell Reports; 2018 Jan; 10(1):212-227. PubMed ID: 29249663
[TBL] [Abstract][Full Text] [Related]
51. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
52. DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer.
Kurani H; Razavipour SF; Harikumar KB; Dunworth M; Ewald AJ; Nasir A; Pearson G; Van Booven D; Zhou Z; Azzam D; Wahlestedt C; Slingerland J
Clin Cancer Res; 2022 May; 28(9):1948-1965. PubMed ID: 35135840
[TBL] [Abstract][Full Text] [Related]
53. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
[TBL] [Abstract][Full Text] [Related]
54. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
55. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.
Jiang T; Zhu J; Jiang S; Chen Z; Xu P; Gong R; Zhong C; Cheng Y; Sun X; Yi W; Yang J; Zhou W; Cheng Y
Adv Sci (Weinh); 2023 Jun; 10(17):e2207257. PubMed ID: 37096846
[TBL] [Abstract][Full Text] [Related]
56. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
[TBL] [Abstract][Full Text] [Related]
57. Metabolic stress induces GD2
Jaggupilli A; Ly S; Nguyen K; Anand V; Yuan B; El-Dana F; Yan Y; Arvanitis Z; Piyarathna DWB; Putluri N; Piwnica-Worms H; Manning HC; Andreeff M; Battula VL
Br J Cancer; 2022 Mar; 126(4):615-627. PubMed ID: 34811508
[TBL] [Abstract][Full Text] [Related]
58. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
59. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
60. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
Luo N; Zhang K; Li X; Hu Y
J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
